Abcellera Biologics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $4,050 | $8,315 | $44,853 | $8,955 |
Gross Profit | 4,050 | -340 | 36,933 | 8,955 |
EBITDA | -41,527 | -40,882 | -11,579 | -66,313 |
EBIT | -58,965 | -49,537 | -19,499 | -73,549 |
Net Income | -55,427 | -43,165 | -8,945 | -57,119 |
Net Change In Cash | 4,050 | 8,315 | 44,853 | 8,955 |
Free Cash Flow | -35,995 | -37,354 | -44,586 | -61,522 |
Cash | 120,065 | 77,063 | 128,513 | 83,159 |
Basic Shares | 305,557 | 303,074 | 298,707 | 298,875 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $75,128 | $28,833 | $38,025 | $485,424 |
Gross Profit | 46,307 | 28,833 | 38,025 | 418,988 |
EBITDA | -148,774 | -204,148 | -192,158 | 260,167 |
EBIT | -177,595 | -301,146 | -223,052 | 227,065 |
Net Income | -146,412 | -162,857 | -146,398 | 158,519 |
Net Change In Cash | 75,128 | 28,833 | 38,025 | 485,424 |
Cost of Revenue | -76,893 | |||
Free Cash Flow | -174,067 | -186,952 | -121,384 | 204,700 |
Cash | 128,513 | 156,325 | 133,320 | 386,535 |
Basic Shares | 298,707 | 294,327 | 289,166 | 314,827 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.18 |
2026-03-31 | -$0.14 |
2025-12-31 | -$0.03 |
2025-09-30 | -$0.19 |